HiFiBiO Therapeutics has been named as one of Fierce Biotech’s Fierce 15 of 2023!
Navigation
About
Vision & Mission
Leadership
SAB
Scientific Founders
Investors
Pipeline
Science
Platform
Publications and Presentations
News
Activities
Company Milestones
R&D
Partnering
Business Development
Open-Innovation Laboratory
Careers
Contact
Publications and Presentations
Publications and Presentations
Scientific
HFB200301
American Society of Clinical Oncology
|
Poster
|
April 27, 2022
Phase I study of HFB200301, a First-in-Class TNFR2 agonist monoclonal antibody in patients with solid tumors selected via Drug Intelligent Science (DIS™)
Phase I study of HFB200301, a First-in-Class TNFR2 agonist monoclonal antibody in patients with solid tumors selected via Drug Intelligent Science (DIS™)
American Association for Cancer Research
|
Presentation
|
April 12, 2021
Mechanism of Action and Biomarker Strategy for HFB200301, an Anti-TNFR2 Agonist Antibody for the Treatment of Cancer
American Association for Cancer Research
|
Poster
|
July 03, 2020
Discovery and characterization of novel TNFR2 antibodies to modulate T cell activities in immunosuppressive environment
Discovery and characterization of novel TNFR2 antibodies to modulate T cell activities in immunosuppressive environment
HFB301001
European Society for Medical Oncology Congress
|
Poster
|
September 12, 2022
Phase I study of HFB301001, a novel OX40 agonist monoclonal antibody, in patients with solid tumors selected via Drug Intelligence Science (DIS™)
Phase I study of HFB301001, a novel OX40 agonist monoclonal antibody, in patients with solid tumors selected via Drug Intelligence Science (DIS™)
American Association for Cancer Research
|
Presentation
|
April 12, 2021
Clinical approach and biomarker strategy for HFB301001, a novel OX40 agonistic antibody
American Association for Cancer Research
|
Poster
|
July 03, 2020
HFB301001, a novel OX40 agonistic antibody with a unique pharmacological profile and innovative biomarker strategy
HFB301001, a novel OX40 agonistic antibody with a unique pharmacological profile and innovative biomarker strategy
HFB200603
American Association for Cancer Research
|
Poster
|
April 13, 2022
HFB200603, a novel anti-BTLA monoclonal antibody that provides therapeutic potential for immune escape and synergizes with anti-PD-1 treatment
HFB200603, a novel anti-BTLA monoclonal antibody that provides therapeutic potential for immune escape and synergizes with anti-PD-1 treatment
HFB200902
American Association for Cancer Research
|
Presentation
|
April 12, 2021
HFB9-2, a novel Galectin 9 neutralizing antibody for the treatment of AML and other cancers
Nature Scientific
|
Publication
|
March 04, 2021
Serial transplantation unmasks galectin‐9 contribution to tumor immune escape in the MB49 murine model
Serial transplantation unmasks galectin‐9 contribution to tumor immune escape in the MB49 murine model
American Association for Cancer Research
|
Poster
|
July 03, 2020
HFB9-2, a novel Galectin-9 neutralizing antibody to reverse immune suppression in the tumor microenvironment
HFB9-2, a novel Galectin-9 neutralizing antibody to reverse immune suppression in the tumor microenvironment
HFB101110
American Association for Cancer Research
|
Poster
|
April 18, 2022
Targeting regulatory T cells with HFB101110, a novel anti-human CCR8 antibody for the treatment of solid tumors
Targeting regulatory T cells with HFB101110, a novel anti-human CCR8 antibody for the treatment of solid tumors
HFB100204
American Association for Cancer Research
|
Presentation
|
April 12, 2021
Discovery and characterization of a novel anti-human CXCR5 antibody for the treatment of B cell lymphomas
Platform
American Association for Cancer Research
|
Poster
|
April 08, 2022
Discovery of predictive biomarkers of response to T cell-targeting biologics using ex vivo single-cell profiling coupled with TCR clonotype characterization
Discovery of predictive biomarkers of response to T cell-targeting biologics using ex vivo single-cell profiling coupled with TCR clonotype characterization
Science Advances
|
Publication
|
June 11, 2021
High-throughput functional screening for next-generation cancer immunotherapy using droplet-based microfluidics
High-throughput functional screening for next-generation cancer immunotherapy using droplet-based microfluidics
American Association for Cancer Research
|
Presentation
|
September 17, 2020
HiFiBiO Therapeutics Presents Novel Approach to Patient Stratification Demonstrating DIS™ Single-Cell Platform at 2020 AACR Tumor Heterogeneity Conference
Nature Biotechnology
|
Publication
|
March 30, 2020
High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics
High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics
Nature Genetics
|
Publication
|
May 31, 2019
High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer
High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer
Nature Biotechnology
|
Publication
|
September 11, 2017
Single-cell deep phenotyping of IgG-secreting cells for high-resolution immune monitoring
Single-cell deep phenotyping of IgG-secreting cells for high-resolution immune monitoring
HiFiBio, Paris
|
Poster
|
November 13, 2016
Antibody Discovery by Deep Mining of Immune Repertoires: A demonstration of the HiFiBiO CelliGO™ Platform versatility and robustness with Tetanus Toxoid antigen as a case study
Antibody Discovery by Deep Mining of Immune Repertoires: A demonstration of the HiFiBiO CelliGO™ Platform versatility and robustness with Tetanus Toxoid antigen as a case study
Other Programs
Frontiers in Pharmacology
|
Publication
|
May 23, 2023
Safety, tolerability, pharmacokinetics, and immunogenicity of an anti-SARS-CoV-2 monoclonal antibody HFB30132A after single dose intravenous administration in healthy Chinese subjects: a phase 1, randomized, double-blind, placebo-controlled study
Safety, tolerability, pharmacokinetics, and immunogenicity of an anti-SARS-CoV-2 monoclonal antibody HFB30132A after single dose intravenous administration in healthy Chinese subjects: a phase 1, randomized, double-blind, placebo-controlled study
Science
|
Publication
|
October 22, 2021
Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study
Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study
Nature Communications
|
Publication
|
May 11, 2021
A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes
A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes
Strategy
Drug Discovery Today
|
Publication
|
May 2023
Global or local: The future of biotech
Global or local: The future of biotech
Drug Discovery Today
|
Publication
|
October 2017
Guiding principles of value creation through collaborative innovation in pharmaceutical research
Guiding principles of value creation through collaborative innovation in pharmaceutical research
Our Story
Biotech2050
|
Podcast
|
June 14, 2023
|
30m 57s
CEO Liang Schweizer speaks with Rahul Chaturvedi on the Biotech2050 Podcast about her journey from scientist to first-time CEO and how HiFiBiO is improving the success rate of immunotherapies by leveraging unprecedented single-cell level insights into patient heterogeneity.
Life Science Success Podcast
|
Podcast
|
January 5, 2023
|
28m 18s
CEO Liang Schweizer spoke with Don Davis on the Life Science Success Podcast about her professional journey and how HiFiBiO is using DIS® to accelerate the delivery of precision immunotherapies to patients.
Dealmakers Show
|
Podcast
|
September 9, 2022
|
35m
CEO Liang Schweizer appeared on the Dealmakers Show by Alejandro Cremades to share the advantages of starting global, managing remote working in drug discovery, building a strong global culture, and how she raised over $180 million in funding.
Talking Biotech Podcast
|
Podcast
|
August 20, 2022
|
52m 03s
CEO Liang Schweizer shared her thoughts and experience with Kevin Folta on the Talking Biotech podcast on how HiFiBiO is using single-cells and microfluidics to identify new antibodies, as well as what could guide application of the most effective treatments.
Lioness Magazine Interview
|
Interview
|
March 11, 2021
|
35m 23s
CEO Liang Schweizer shared with Lioness Magazine how HiFiBiO combines biological expertise with single-cell profiling technologies to advance antibody drugs. She also highlighted the importance of community service and mentorship to her successes.
Genialis Podcast
|
Podcast
|
February 26, 2021
|
51m 07s
CEO Liang Schweizer spoke with Rafael Rosengarten from Genialis about Drug Intelligence Science (DIS®) that combines data intelligence with single-cell science to achieve optimal outcomes for all stages of drug discovery and development.
PharmaBoardRoom Article
|
Article
|
February 17, 2021
CEO Liang Schweizer introduced HiFiBiO Therapeutics, the main advantages of the company’s unique single-cell technology platform, its open innovation approach, experience with capital markets, and advice for other biotech leaders.
BioBoss Podcast
|
Podcast
|
September 29, 2019
|
48m
CEO Liang Schweizer interviewed with John Simboli on the BioBoss podcast to share her perspectives on biotech leadership and highlight the uniqueness of HiFiBiO’s single-cell driven Drug Intelligence Science (DIS®) approach and highly diverse teams.